1
|
Leighl N, Alexandru A, Ohe Y, Ruff P, Hida T, Nishio M, Rothenstein J, Tomiak A, Lowry P, Kumagai T, Gore I, Ntambwe I, Marimuthu S, Schenker M. FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Nagasaka M, Goto K, Gomez J, Hida T, Shu C, Lee C, Park K, Cho B, Lee J, Ou S, Bestvina C, Natale R, Haddish-Berhane N, Bhattacharya A, Verheijen R, Agrawal T, Knoblauch R, Govindan R. P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Hida T, Nishino M, Yoh K, Asato T, Kitagawa T, Zhang S, Mehta M, Ohe Y. 1246P A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2021; 32:1137-1147. [PMID: 34139272 DOI: 10.1016/j.annonc.2021.06.004] [Citation(s) in RCA: 83] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Revised: 05/26/2021] [Accepted: 06/10/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Between June 2017 and July 2019, this study enrolled treatment-naïve patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations. They were randomly assigned in a 1 : 1 ratio to receive nivolumab or placebo in combination with carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles, followed by nivolumab/placebo with bevacizumab until progressive disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by an independent radiology review committee (IRRC). RESULTS Overall, 550 patients from Japan, Korea, and Taiwan were randomized; of these patients, 273 and 275 received the nivolumab and placebo combinations, respectively. In the present preplanned interim analysis with a median follow up of 13.7 months, the IRRC-assessed median PFS was significantly longer in the nivolumab arm than in the placebo arm (12.1 versus 8.1 months; hazard ratio 0.56; 96.4% confidence interval 0.43-0.71; P < 0.0001). The PFS benefit was observed across all patients with any programmed death-ligand 1 (PD-L1) expression levels including PD-L1-negative patients. The IRRC-assessed objective response rates were 61.5% and 50.5% in the nivolumab and placebo arms, respectively. The incidence of treatment-related adverse events of grade 3 or 4 was comparable between the two arms; treatment-related adverse events leading to death were observed in five and four patients in the nivolumab and placebo arms, respectively. CONCLUSION The TASUKI-52 regimen should be considered a viable new treatment strategy for treatment-naïve patients with advanced nonsquamous NSCLC.
Collapse
Affiliation(s)
- S Sugawara
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan
| | - J-S Lee
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea
| | - J-H Kang
- Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea
| | - H R Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - N Inui
- Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan
| | - T Hida
- Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan
| | - K H Lee
- Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, Korea
| | - T Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - H Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | - C-T Yang
- Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - M Nishio
- Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - Y Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - T Tamura
- Thoracic Center, St. Luke's International Hospital, Tokyo, Japan
| | - N Yamamoto
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan
| | - C-J Yu
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - H Akamatsu
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan
| | - Y Namba
- Clinical Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan
| | - N Sumiyoshi
- Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
| |
Collapse
|
5
|
Han J, Wolf J, Garon E, Groen H, Heist R, Ang M, Ohashi K, Toyozawa R, Kim T, Hida T, Takeda M, Sugawara S, Chang W, Yu C, Moizumi S, Robeva A, Le Mouhaer S, Waldron-Lynch M, Chassot Agostinho A, Myers A, Nishio M. P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Goto K, Hida T, Funami N, Iwasawa R, Mita S, Botilde Y, Yamashita A, Inoh Y, Haddish-Berhane N, Xie J, Roshak A, Knoblauch R, Ohe Y. P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.540] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Heist R, Vansteenkiste J, Smit E, Groen H, Garon E, Hida T, Nishio M, Kokowski K, Grohe C, Reguart N, Mansfield A, Robeva A, Ghebremariam S, Waldron-Lynch M, Akimov M, Nwana N, Giovannini M, Wolf J. MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
8
|
Lee JS, Sugawara S, Kang J, Kim H, Inui N, Hida T, Lee K, Yoshida T, Tanaka H, Yang C, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2287] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Hayashi H, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Hirano J, Namba Y, Ohe Y. 1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
10
|
Vansteenkiste J, Smit E, Groen H, Garon E, Heist R, Hida T, Nishio M, Kokowski K, Grohe C, Reguart N, Mansfield A, Robeva A, Ghebremariam S, Waldron-Lynch M, Akimov M, Nwana N, Giovannini M, Wolf J. 1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1599] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Heist R, Wolf J, Seto T, Han JY, Reguart N, Groen H, Tan D, Hida T, Jonge M, Orlov S, Smit E, Souquet PJ, Vansteenkiste J, Giovannini M, Mouhaer S, Robeva A, Waldron-Lynch M, Garon E. OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Yamaguchi T, Oya Y, Furuta H, Watanabe N, Uemura T, Shimizu J, Horio Y, Hida T. EP1.01-32 Improving the Prognosis of Non-Small Cell Lung Cancer After the Approval of Immune Checkpoint Inhibitors: A Retrospective Analysis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF, Akita H, Chan OSH, Piperdi B, Burke T, Khambata-Ford S, Deitz AC. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. Lung Cancer 2019; 134:174-179. [PMID: 31319978 DOI: 10.1016/j.lungcan.2019.06.012] [Citation(s) in RCA: 78] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 06/05/2019] [Accepted: 06/11/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVES Tumor programmed death ligand 1 (PD-L1) expression is associated with improved clinical benefit from immunotherapies targeting the PD-1 pathway. We conducted a global, multicenter, retrospective observational study to determine real-world prevalence of tumor PD-L1 expression in patients with NSCLC. MATERIALS AND METHODS Patients ≥18 years with histologically confirmed stage IIIB/IV NSCLC and a tumor tissue block (≤5 years old) obtained before treatment were identified in 45 centers across 18 countries. Tumor samples from eligible patients were selected consecutively, when possible. PD-L1 expression was evaluated at each center using the PD-L1 IHC 22C3 pharmDx kit (Agilent, Santa Clara, CA, USA). RESULTS Of 2617 patients who met inclusion criteria, 2368 (90%) had PD-L1 data; 530 (22%) patients had PD-L1 TPS ≥ 50%, 1232 (52%) had PD-L1 TPS ≥ 1%, and 1136 (48%) had PD-L1 TPS < 1%. The most common reason for not having PD-L1 data (n = 249) was insufficient tumor cells (<100) on the slide (n = 170 [6%]). Percentages of patients with PD-L1 TPS ≥ 50% and TPS ≥ 1%, respectively were: 22%/52% in Europe; 22%/53% in Asia Pacific; 21%/47% in the Americas, and 24%/55% in other countries. Prevalence of EGFR mutations (19%) and ALK alterations (3%) was consistent with prior reports from metastatic NSCLC studies. Among 1064 patients negative for both EGFR mutation and ALK alteration, the percentage with PD-L1 TPS ≥ 50% and TPS ≥ 1%, respectively, were 27% and 53%. CONCLUSIONS This is the largest real-world study in advanced NSCLC to date evaluating PD-L1 tumor expression using the 22C3 pharmDx kit. Testing failure rate was low with local evaluation of PD-L1 TPS across a large number of centers. Prevalence of PD-L1 TPS ≥ 50% and TPS ≥ 1% among patients with stage IIIB/IV NSCLC was similar across geographic regions and broadly consistent with central testing results from clinical trial screening populations.
Collapse
Affiliation(s)
- M Dietel
- Institute of Pathology, Charité, University Medicine Berlin, Berlin, Germany.
| | - N Savelov
- Department of Pathology, Moscow City Oncology Hospital #62, Moscow, Russian Federation
| | - R Salanova
- Department of Pathology, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina
| | - P Micke
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| | - G Bigras
- Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - T Hida
- Department of Thoracic Oncology, Aichi Cancer Center, Nagoya, Japan
| | - J Antunez
- Pathology Department, University Hospital of Santiago de Compostela, La Coruña, Spain
| | | | - G Hutarew
- Institute of Pathology, University Hospital and Paracelsus Medical University Salzburg, Salzburg, Austria
| | - L F Sua
- Department of Pathology and Laboratory Medicine, Clinical Research Center, Fundación Valle del Lili, Cali, Colombia
| | - H Akita
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - O S H Chan
- Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
| | - B Piperdi
- Merck & Co., Inc., Kenilworth, NJ, USA
| | - T Burke
- Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA
| | | | - A C Deitz
- Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA
| |
Collapse
|
14
|
Hida T, Okura M, Kamiya T, Yamamoto M, Hori T, Uhara H. A case of childhood-onset cutaneous mastocytosis with loss of wild-type KIT allele. J Eur Acad Dermatol Venereol 2019; 33:e235-e237. [PMID: 30773694 DOI: 10.1111/jdv.15501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T Hida
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - M Okura
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - T Kamiya
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - M Yamamoto
- Department of Pediatrics, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - T Hori
- Department of Pediatrics, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - H Uhara
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| |
Collapse
|
15
|
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han J, Hida T, Moro-Sibilot D, Conkling P, Gandara D, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer 2019; 107:124-132. [DOI: 10.1016/j.ejca.2018.11.020] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 11/09/2018] [Indexed: 01/05/2023]
|
16
|
Halmos B, Tan E, Soo R, Cadranel J, Ki Lee M, Foucher P, Hsia T, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E. Impact de la dose d’afatinib sur la tolérance et l’efficacité en vie réelle chez des patients avec CBNPC avancé EGFR muté. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Yamaguchi T, Morikawa S, Yuko O, Asada K, Oguri T, Inui N, Ito K, Kimura T, Kunii E, Matsui T, Kubo A, Kato T, Shindo J, Tsuda T, Okuno M, Hida T, Imaizumi K. P083 Efficacy of EGFR-TKIs in Patients Harboring EGFR Mutations with Non-Adenocartinoma Histology. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
Yamaguchi T, Hasegawa T, Hanai N, Inaba Y, Muro K, Hida T. Risk factors of nivolumab-induced pneumonitis in patients with solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy441.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Tanaka K, Inui N, Asada K, Abe T, Hataji O, Hayai S, Ito K, Imaizumi K, Kimura T, Kubo A, Kunii E, Murotani K, Okuno M, Oya Y, Shindoh J, Taniguchi H, Tsuda T, Yamaguchi T, Hida T, Suda T. Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Viteri S, Chang GC, Chiari R, Cho B, Ciardiello F, Curigliano G, Hida T, Lee D, Lim W, Lin CC, Martinez A, Murakami H, Natsume I, Nishio M, Paz-Ares L, Soo R, Cattan V, Gandossi E, Heck H, Park K. Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.074] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Nakano T, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Ohe Y. OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.275] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Hida T, Lydon C, Hatabu H, Johnson B, Awad M, Nishino M. P1.01-35 Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Tan D, Kim SW, Sequist L, Ponce Aix S, Smit E, Hida T, Yang JH, Felip E, Seto T, Grohe C, Wolf J, Ko J, Marriere E, Belli R, Giovannini M, Kim DW. Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.073] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindo J, Asada K, Imaizumi K, Tanaka K, Inui N, Okuno M, Hataji O, Hayai S, Abe T, Kimura T, Tsuda T, Yamaguchi T, Oya Y, Yoshida T, Hida T. Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.077] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Wolf J, Seto T, Han JY, Reguart N, Garon E, Groen H, Tan D, Hida T, de Jonge M, Orlov S, Smit E, Souquet PJ, Vansteenkiste J, Giovannini M, Le Mouhaer S, Robeva A, Waldron-Lynch M, Heist R. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.090] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Halmos B, Tan E, Soo R, Cadranel J, Lee M, Foucher P, Hsia T, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E. P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Salanova R, Dietel M, Savelov N, Micke P, Bigras G, Hida T, Piperdi B, Burke T, Khambata-Ford S, Deitz A. PD.1.02 Real-World Prevalence of PD-L1 Expression in Advanced Non–Small-Cell Lung Cancer: The Global, Multicenter EXPRESS Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Minowa T, Kato J, Hida T, Horimoto K, Sato S, Sawada M, Takahashi H, Uhara H. Granulocyte colony-stimulating factor-producing melanoma treated with the combination of dabrafenib and trametinib. Int J Dermatol 2018; 57:e31-e33. [PMID: 29655274 DOI: 10.1111/ijd.14004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 02/12/2018] [Accepted: 03/18/2018] [Indexed: 12/01/2022]
Affiliation(s)
- T Minowa
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - J Kato
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - T Hida
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - K Horimoto
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - S Sato
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - M Sawada
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - H Takahashi
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - H Uhara
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
| |
Collapse
|
29
|
Sawada M, Hida T, Ujiie H, Iwata H, Uhara H. A case of subepidermal autoimmune bullous disease with autoantibodies against 200 and 290-kDa antigens. J Eur Acad Dermatol Venereol 2018. [PMID: 29524251 DOI: 10.1111/jdv.14927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- M Sawada
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - T Hida
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| | - H Ujiie
- Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
| | - H Iwata
- Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan
| | - H Uhara
- Department of Dermatology, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-ku, Sapporo, 060-8543, Japan
| |
Collapse
|
30
|
Kato J, Hida T, Sugita S, Hasegawa T, Kamiya S, Horimoto K, Sato S, Sawada M, Uhara H. Cytokeratin 19 expression is a risk factor for metastasis in cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol 2018; 32:e299-e301. [DOI: 10.1111/jdv.14845] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- J. Kato
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - T. Hida
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - S. Sugita
- Surgical Pathology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - T. Hasegawa
- Surgical Pathology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - S. Kamiya
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - K. Horimoto
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - S. Sato
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - M. Sawada
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| | - H. Uhara
- Department of Dermatology; Sapporo Medical University School of Medicine; Sapporo Japan
| |
Collapse
|
31
|
Nakamura A, Udagawa H, Matsumoto S, Sugawara S, Shingyoji M, Horiike A, Okamoto I, Hida T, Saeki S, Ohe Y, Ogawara D, Kataoka Y, Miyata Y, Mitsufuji H, Kuyama S, Kanemaru R, Kato T, Hirata A, Yoh K, Goto K. Prevalence of NTRK gene fusions in a large cohort of Japanese patients with lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Yamaguchi T, Oya Y, Kagawa Y, Furuta H, Watanabe N, Shimizu J, Horio Y, Uemura T, Morikawa S, Imaizumi K, Hida T. P2.07-028 Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer Patients Who Relapse after Thoracic Radiotherapy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Satouchi M, Fehrenbacher L, Dols MC, Han J, Von Pawel J, Bordoni R, Hida T, Park K, Moro-Sibilot D, Conkling P, Matheny C, Yu W, He P, Kowanetz M, Gandhi M, Ballinger M, Sandler A, Gandara D. OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.432] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Nishio M, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Takeuchi K, Inamura S, Kuriki H, Shimada T, Tamura T. OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Goto Y, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Ohe Y. MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.634] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
36
|
Ono A, Takahashi T, Niho S, Yoshida T, Akimoto T, Sakamaki K, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. MA 17.06 Safety Data from Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined with TRT for Locally Advanced Non-Squamous NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Misumi Y, Shimokawa T, Okamoto H, Atagi S, Tanaka H, Goto K, Nakagawa K, Hida T, Yamamoto N, Hosomi Y, Kato T, Okamoto I, Ohe Y. P2.15-004 Underrepresentation of Elderly Patients with ED-SCLC as Clinical Trial Candidates (JCOG1201/TORG1528). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Sequist L, Wu Y, Schuler M, Kato T, Yang J, Tanaka H, Hida T, Lu S, Park K, Paz-Ares L, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Tang W, Ehrnrooth E, Yamamoto N, Nakagawa K. PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.058] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T, Nishio M. Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Park K, Ciardiello F, Hida T, Lim W, Lin CC, Murakami H, Nishio M, Cantero F, Cattan V, Gabarroca C, Gandossi E, Paz-Ares L. Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.080] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Mitsudomi T, Ahn MJ, Bazhenova L, Blackhall F, Hida T, Majem Tarruella M, Vowler S, Laus G, Jänne P, Yang JH. Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.050] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Niho S, Yoshida T, Akimoto T, Sakamaki K, Takahashi T, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx379.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Sequist L, Wu YL, Schuler M, Kato T, Yang JH, Tanaka H, Hida T, Lu S, Park K, Laurie S, Bennouna J, Moro Sibilot D, Märten A, Peil B, Ehrnrooth E, Yamamoto N, Nakagawa K. Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Schütte W, Barlesi F, Park K, Ciardiello F, Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara DR, Barrios C, Chen DS, He P, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. Pneumologie 2017. [DOI: 10.1055/s-0037-1598278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- W Schütte
- Klinik für Innere Medizin, Klinik für Innere Medizin II, Städtisches Krankenhaus Martha Maria, Halle (Saale)
| | - F Barlesi
- Assistance Publique Hôpitaux de Marseille, Aix Marseille University
| | - K Park
- Sungkyunkwan University School of Medicine
| | | | - J Pawel
- Asklepios-Fachkliniken München-Gauting
| | - S Gadgeel
- Karmanos Cancer Institute/Wayne State University
| | - T Hida
- Aichi Cancer Center Hospital
| | - D Kowalski
- Oncology Centre, Institute M. Sklodowska – Curie
| | - M Cobo Dols
- Medical Oncology Section, Hospital Regional Universitario Carlos Haya
| | | | | | - J Polikoff
- Southern California Permanente Medical Group
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Park K, Barlesi F, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, Kowanetz M, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. 438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Oya Y, Yoshida T, Tanaka K, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Hida T, Yatabe Y. 448PD Association between EGFR T790M status and progression patterns during initial EGFR-TKIs treatment in patients harboring EGFR mutation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Velcheti V, Hida T, Reckamp K, Yang J, Nokihara H, Sachdev P, Feit K, Kubota T, Nakada T, Dutcus C, Ren M, Tamura T. Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.05] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, Kowanetz M, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.43] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Hida T, Oya Y, Tanaka K, Yoshida T, Shimizu J, Horio Y, Yatabe Y, Itoh T, Shin W. 12P Volatolomic signatures of anaplastic lymphoma kinase gene rearrangement in adenocarcinoma. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30126-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
50
|
Kitao M, Hida T, Eguchi N, Tobita H, Utsugi H, Uemura A, Kitaoka S, Koike T. Light compensation points in shade-grown seedlings of deciduous broadleaf tree species with different successional traits raised under elevated CO2. Plant Biol (Stuttg) 2016. [PMID: 26404633 DOI: 10.1046/j.1365-3040.2000.00528.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
We measured leaf photosynthetic traits in shade-grown seedlings of four tree species native to northern Japan, raised under an elevated CO2 condition, to investigate the effects of elevated CO2 on shade tolerance of deciduous broadleaf tree species with different successional traits. We considered Betula platyphylla var. japonica and Betula maximowicziana as pioneer species, Quercus mongolica var. crispula as a mid-successional species, and Acer mono as a climax species. The plants were grown under shade conditions (10% of full sunlight) in a CO2 -regulated phytotron. Light compensation points (LCPs) decreased in all tree species when grown under elevated CO2 (720 μmol·mol(-1) ), which were accompanied by higher apparent quantum yields but no photosynthetic down-regulation. LCPs in Q. mongolica and A. mono grown under elevated CO2 were lower than those in the two pioneer birch species. The LCP in Q. mongolica seedlings was not different from that of A. mono in each CO2 treatment. However, lower dark respiration rates were observed in A. mono than in Q. mongolica, suggesting higher shade tolerance in A. mono as a climax species in relation to carbon loss at night. Thus, elevated CO2 may have enhanced shade tolerance by lowering LCPs in all species, but the ranking of shade tolerance related to successional traits did not change among species under elevated CO2 , i.e. the highest shade tolerance was observed in the climax species (A. mono), followed by a gap-dependent species (Q. mongolica), while lower shade tolerance was observed in the pioneer species (B. platyphylla and B. maximowicziana).
Collapse
Affiliation(s)
- M Kitao
- Department of Plant Ecology, Forestry and Forest Products Research Institute, Tsukuba, Japan
| | - T Hida
- Department of Forest Science, Hokkaido University, Sapporo, Japan
| | - N Eguchi
- Department of Forest Science, Hokkaido University, Sapporo, Japan
| | - H Tobita
- Department of Plant Ecology, Forestry and Forest Products Research Institute, Tsukuba, Japan
| | - H Utsugi
- Department of Plant Ecology, Forestry and Forest Products Research Institute, Tsukuba, Japan
| | - A Uemura
- Hokkaido Research Center, Forestry and Forest Products Research Institute, Sapporo, Japan
| | - S Kitaoka
- Department of Plant Ecology, Forestry and Forest Products Research Institute, Tsukuba, Japan
| | - T Koike
- Department of Forest Science, Hokkaido University, Sapporo, Japan
| |
Collapse
|